Monrovia, United States
Cell Care Therapeutics, founded in 2014, is at the forefront of innovating stem cell-derived biopharmaceuticals. Specializing in the biopharma, biotechnology, and pharmaceutical industries, the company focuses on treating inflammatory and degenerative ophthalmic diseases. Their slogan, "Developing first-in-class stem cell derived biopharmaceuticals to treat inflammatory and degenerative ophthalmic diseases," underscores this mission.
By leveraging a novel secretome platform, Cell Care Therapeutics is pioneering in harnessing signaling molecules from mesenchymal stromal cells. This is designed to enhance vascular health, with their initial product targeting diabetic macular edema, a major cause of vision loss among working-age adults. Headquartered in the United States, the company is strategically positioned in the global biopharmaceutical market.
In its most recent financing round, Cell Care Therapeutics secured a $4.30M seed investment on 01 October 2018. This injection of capital highlights the market's confidence in the company's innovative approach and potential for transformative impact in ophthalmic treatments.
